INS and type 2 diabetes mellitus: In regard to combination therapy, a study of combination therapy of insulin and sitagliptin, a dipeptidyl peptidase‐4 inhibitor, in type 2 diabetes patients for 24 weeks showed that the addition of sitagliptin to inadequate glycemic control receiving stable insulin therapy with or without metformin led to remarkably good glycemic control compared with placebo14.